Clinical trial
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive…
NCT00136292 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00136292 |
|---|---|
| Title | Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics |
| Official title | An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gram-positive Bacterial Infections |
| Intervention type | Drug |
| Interventions | daptomycin |
| Enrollment | 33 |
| Start date | Aug 24, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 9, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Mar 11, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: